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Abstract
Tissue engineering is a rapidly advancing field that is likely to transform how medicine is practised in the near
future. For hollow organs such as those found in the cardiovascular and respiratory systems or gastrointestinal
tract, tissue engineering can provide replacement of the entire organ or provide restoration of function to
specific regions. Larger tissue-engineered constructs often require biomaterial-based scaffold structures to
provide support and structure for new tissue growth. Consideration must be given to the choice of material
and manufacturing process to ensure the de novo tissue closely matches the mechanical and physiological
properties of the native tissue. This review will discuss some of the approaches taken to date for fabricating
hollow organ scaffolds and the selection of appropriate biomaterials.
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Background
Introduction
The increasingly ageing population represents a huge
socioeconomic burden on healthcare systems worldwide.
New therapies are urgently sought that can rejuvenate
or restore function of physiological systems that no lon-
ger function correctly due to the cumulative effects of
wear and tear. Organ transplantation offers a limited
solution due to donor shortages and the need for life-
long immunosuppression [1]. Xenotransplantation con-
tinues to be proposed but has yet to fulfil its promise
due to concerns over long-term stability, immune system
rejection and zoonoses [2]. Despite recent advances in
genome editing for xenotransplantation, there are still
many challenges to overcome before organ transplant
from animals becomes a commonplace [3].
There is therefore a clear need for alternative strat-
egies aimed at producing curative treatments. Tissue
engineering is a rapidly developing interdisciplinary field
that involves both materials science and engineering
with medical research to address clinical problems. The
majority of tissue engineering strategies rely on the use
of biocompatible materials to facilitate tissue regener-
ation. Scaffolds can be manufactured from different
materials and by a variety of methods, depending on the
intended application. Three-dimensional scaffolds have
the ability to guide tissue regrowth, provide support, en-
courage cell adhesion and proliferation, be combined
with biological agents to provide a sustained release of
various factors or drugs, and support neovascularisation
within an interconnected porous network [4–6]. Tissue
engineering can in theory be applied to any part of the
human body, but advances in the bioengineering of
hollow organs have led to several high-profile success
stories in recent years, notably artificial bladders suc-
cessfully transplanted into patients in 2006 [7] and a
trachea implantation in 2008 [8, 9]. The objective of
this review is to discuss different biomaterials and tis-
sue engineering strategies for hollow organs found in
the cardiovascular, respiratory and gastrointestinal
systems.
Scaffold fabrication techniques
There are many different methods available to fabri-
cate scaffolds for tissue engineering. The approach
taken is often determined by the starting material,
scale of the construct, and physiochemical and mech-
anical properties of the scaffold. Techniques that have
been used to produce scaffolds suitable for hollow
organ tissue engineering include electrospinning and
extrusion methods that allow for the production of
* Correspondence: eseelle.hendow.13@ucl.ac.uk
Applied Biomedical Engineering Group, Division of Medicine, University
College London, 21 University Street, London, UK
© 2016 Hendow et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hendow et al. Fibrogenesis & Tissue Repair  (2016) 9:3 
DOI 10.1186/s13069-016-0040-6
polymer fibres or meshes [10–12], thermally induced
phase separation (TIPS) [11], electrohydrodynamic
(EHD) processing [13], 3D printing [14] and hydro-
gels, whose properties can be controlled by changes
on pH or temperature [15].
For a material to be classed as a biomaterial, it must
fulfil certain criteria. The material should be compatible
with cells and tissues in the local milieu so as not to
illicit a chronic inflammatory response. Other desirable
properties may include biodegradation, porosity, specific
mechanical properties and the ability to facilitate cell at-
tachment [16, 17]. Synthetic polymers are often chosen
because their composition and structure can be refined
to meet these specifications. They are often cheaper to
produce than natural polymers, and greater control can
be exerted over the manufacturing processes, which pro-
vides scope for reproducible and scaled-up manufacture.
A widely used class of synthetic polymer is poly(alpha-
hydroxyesters) due to their capacity to offer control of
degradation and porosity which can affect the behaviour
of cells [18–20]. A variety of natural polymers have also
been investigated for use as scaffold materials, such as
collagen and elastin found in the extracellular matrix of
many tissues. These materials are generally considered
to offer better cell-material interactions compared with
synthetic materials since they provide an environment
that resembles native tissue. However, these materials
are often more difficult to manipulate and process into
scaffold structures compared with synthetic materials
[10]. The advantages and disadvantages of some of the
different scaffold fabrication techniques available are
outlined in Table 1.
Bioengineered blood vessels
Cardiovascular diseases are within the top ten causes of
death worldwide, with pathologies including myocardial
infarction, stroke, congestive heart failure, peripheral ar-
terial disease and vascular disease [21]. The need for
curative therapies is clear, and the use of biomaterial
scaffolds alongside cell therapies could provide this [22].
Biomaterials can be utilised in a variety of ways from the
use of microparticles to successfully deliver cells to their
target site [23] to incorporating growth factors or drugs
in a degradable material for their sustained release.
One of the most popular cell types studied in bio-
engineering blood vessels is endothelial cells, which line
arteries and veins and form capillaries. They control the
function of the entire vessel by signalling to the sur-
rounding smooth muscle tissue to response to changes
in shear stress by adapting lumen diameter and wall
thickness [24]. Other cell types within blood vessels
such as smooth muscle cells and pericytes are also
researched to promote angiogenesis [25] and bio-
engineer blood vessels [26].
Whole blood vessels can be produced by various
tissue engineering methods including 3D printing
Table 1 Various fabrication techniques for biomaterial scaffolds
Fabrication method Application Advantages Disadvantages References
Tissue decellularisation Tissues with high ECM content,
e.g. trachea, heart valves
Native composition (ECM), retains
mechanical properties and shape
of organ
Immunogenicity due to incomplete
decellularisation, loss of ECM,
requires donor organ
[5, 10, 78]
Electrohydrodynamic
(EHD) processing
Drug delivery, hard and soft
tissue engineering, wound
healing
Fibres, particles and encapsulated
particle production, biocompatible,
biodegradable, manufacturing
parameters adjustable to tailor
product, control over pore size and
distribution
Inhomogeneous distribution
of seeded cells
[5, 10, 13,
79, 80]
Electrospinning Drug delivery, hard and soft
tissue engineering, wound
healing
Production of fibres and encapsulated
fibres, high porosity, surface area,
biocompatible and biodegradable,
manufacturing parameters adjustable
to tailor product
Inhomogeneous distribution
of seeded cells
[81, 82]
Hydrogels Scaffolds for cartilage,
connective tissue and soft
tissue bioengineering, cell
delivery, drug delivery,
wound healing
Tuneable biodegradability, biomimicry,
biocompatible, improves cellular
interactions, mimics native ECM, injectable,
self-assembly possible in response to pH
and temperature, can be incorporated
with other materials
Limited mechanical properties,
sensitive to the surrounding
environment
[5, 10, 15,
28–31]
Thermally induced phase
separation (TIPS)
Microparticles for tissue
engineering, cell delivery,
drug delivery
High porosity, biocompatible,
biodegradable, 3D scaffold, manufacturing
parameters adjustable to tailor product,
interconnected porous network, cell
proliferation, injectable
Limited open space through
scaffold, inhomogeneous size
particles, particle aggregation
[10, 11, 80]
3D printing Fully developed constructs Complex structures mechanically similar
to native tissue, fast processing
Limited materials,
post-processing
[4, 14, 27]
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[27], 3D patterns on hydrogels [28] and composite
scaffolds [29–31]. Recent studies into whole vessel
engineering have focused on the use of polymer scaffolds
incorporated with hydrogels. Hydrogels are defined as
three-dimensional hydrophilic cross-linked networks that
have the ability to absorb large amounts of water. Hydro-
gels are being increasingly considered as a material of use
in tissue engineering applications due to their ability to
mimic natural tissues and support tissues [32]. Singh et al.
(2013) constructed a polyethylene glycol (PEG)-collagen
composite scaffold containing photoencapsulated endo-
thelial cells and fibroblasts to produce vessel networks
within well-defined hollow lumens [30]. In addition, a
novel method using 3D printing to create patterns on
polycaprolactone (PCL) surfaces coated with gelatin
allowed smooth muscle cells to align to the patterns and
so facilitate blood vessel formation.
New blood vessels have the ability to grow from the
existing vessels throughout adult life in a process called
angiogenesis. Angiogenesis is dependent on growth factors
such as vascular endothelial growth factor (VEGF) and
basic fibroblast growth factor (bFGF), as well as signalling
and interactions between cell types such as endothelial
cells and pericytes [33]. Promotion of angiogenesis
through the use of biomaterials, cell therapies and admin-
istration of growth factors is widely researched.
Bauters et al. (1995) showed that administering VEGF
into a rabbit model of hind limb ischemia resulted in
improved blood vessel formation compared to a control
group after 30 days [34]. Unfortunately, VEGF and other
growth factors have short half-lives, some only minutes
long [35]. Therefore, once an injection is administered,
VEGF begins to degrade. To overcome this, larger doses
or more frequent injections could be given. Excessive
VEGF levels can, however, have oncogenic effects [36].
Another option is to encapsulate VEGF in a biodegrad-
able material so it can be slowly released as the material
degrades. Rocha et al. (2008) encapsulated VEGF in
poly(lactic-co-glycolic acid) (PLGA) microspheres and
implanted them in a tissue-engineered intestine in order
to promote epithelialisation. In vitro and in vivo studies
showed that the microspheres had a sustained release of
active VEGF, and in vivo studies also found that com-
pared to the controls, the group given the VEGF parti-
cles had increased capillary density, epithelial cell
proliferation and larger intestinal constructs [37]. Cell
therapy can also be used to promote angiogenesis by en-
couraging vessel formation by implanting stem cells or
cells found in blood vessels to initiate angiogenesis by
producing growth factors. Chen et al. (2005) implanted
bone marrow stromal cells into the ischemic boundary
zone after rats had a stroke. Results also showed that the
rats implanted with cells have significantly higher VEGF
levels which accounts for the enlarged blood vessels and
newly formed capillaries in comparison to rats treated
with phosphate buffered saline (PBS) [38]. Numerous
studies have shown that simply injecting cells into ische-
mic tissue can result in a large cell loss from the target
site. Hong et al. (2013) showed that 1 day after stem
cells were injected into heart infarcts, only 10 % of cells
remained at the injection site [23]. An alternative solu-
tion is to utilise cell-based biomaterial therapies, specif-
ically the use of microspheres, to allow adhesion to the
implant site and allow cells to attach and proliferate,
increasing the residence time of cells and consequently
enhancing their therapeutic effect. Promoting the regen-
eration of blood vessels through angiogenesis or engin-
eering entire constructs can treat a variety of
cardiovascular diseases as well as being vital for the sur-
vival of engineered tissues by allowing vascularisation.
Gastrointestinal tissue engineering
The gastrointestinal (GI) tract consists of the oesophagus,
stomach, small and large intestines and colon. It is a com-
plex hollow organ system with diverse functions and
structures that facilitate digestion, absorption of nutrients
and excretion of waste from the body. Engineered GI tis-
sue can be applied to repair damage caused by stomach
cancer, inflamatory bowel disease, as well as replace
sphincter tissue to cure faecal and urinary incontinence.
Stomach cancer is the fourth most common fatal can-
cer in Europe [39]. Gastrectomy is the recommended
treatment for stomach cancer (alongside chemotherapy
and radiotherapy if the cancer has metastasised) [40] but
has adverse side effects such as malnutrition, reflux
esophagitis, osteomalacia and anaemia. The alternative is
to remove just the cancerous tissue in order to preserve
the stomach; however, as a result of this, the stomach
often becomes distorted and unable to function fully.
The stomach is notoriously difficult to engineer due to
its shape and scale, and as a result, relatively few studies
have addressed this need [40]. Rather than attempting to
directly replicate the native stomach, more attention has
been placed on producing tubular constructs and
patches. Othman et al. (2015) cultured cells on collagen
and polyethylene terephthalate (PET) sheets that were
rolled into 3D scaffolds by an automated tube fabricator.
By using this method, they were able to produce large
constructs with appropriate thickness, length and luminal
diameter for gastrointestinal tissue engineering applica-
tions [41]. To repair patches of tissue after resection,
typically a biodegradable material is used. There have been
a few studies that have used polyglycolic acid (PGA) and
poly-L-lactic acid (PLLA) seeded with endothelial cells
from the stomach. Maemura et al. (2008) implanted these
constructs in an in vivo rat model. They found that the
cells on the tissue-engineered scaffold had comparable
secretory functions to a native stomach [42]. The same
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group also demonstrated that there was less deformity
and a smaller volume loss when the tissue-engineered
construct was implanted into a gastrointestinal deformity
compared to controls [43]. Another group, Sala et al.
(2009), successfully implanted a tissue-engineered stom-
ach and small intestine (PGA and PLLA seeded with au-
tologous stomach-derived organoid units) into an in vivo
swine model. Histological analysis showed all intestinal
cell types present after 7 weeks on the scaffold as well as
mucus cells present in the stomach. These pre-clinical
studies show that it is possible to generate a tissue-
engineered construct at a large scale with the correct
architecture, ability to facilitate cell attachment and prolif-
eration, suggesting that it could be possible in humans re-
quiring gastrointestinal transplants [44]. Unfortunately, to
date, all of these studies have remained at the pre-clinical
stage of development.
Inflammatory bowel disease (IBD) affects 1 in 250
people in the UK with the most prevalent examples
being ulcerative colitis (UC) and Crohn’s disease. Both
diseases are lifelong, with Crohn’s primarily affecting the
small intestine and UC the large intestine [45]. In the
UK, 20 % of people with UC and 60 % with Crohn’s will
have to have surgery, and often, portions of the GI sys-
tem are removed [46]. These surgeries are highly inva-
sive and can result in stoma complications, short bowel
syndrome and malnutrition [47]. Intestinal tissue engin-
eering predominately focuses on the small intestine.
Numerous in vivo studies have focused on large animal
models using collagen sponge scaffolds seeded with in-
testinal smooth muscle to repair patches of intestinal
tissue. Despite limited success with formation of epithe-
lial layers, these studies have found it difficult to repli-
cate the alignment and contractile function of smooth
muscle cells in vivo which is vital for sufficient nutrient
absorption [48–50]. An alternative cell source such as
intestinal organoid units have also been used alongside
biomaterials for small intestinal tissue engineering.
Gritscheit et al.(2004) successfully lengthening short
bowel defects in canine models of short bowel syndrome
[51, 52]. Similarly for the small intestine, the large intes-
tine requires the formation of longitudinal and circular
smooth muscle layers to allow for peristalsis. Bitar et al.
(2013) co-cultured smooth muscle cells with intestinal
organoid units to produce circular constructs that were
wrapped around tubular collagen scaffolds to resemble
the native colon. Mechanical and physiological studies
showed successful contractility in the construct, which is
a promising step to engineer a functional intestine. Fur-
ther in vivo studies are required to assess whether or not
peristalsis can be replicated [53, 54].
Faecal incontinence is a major public health issue with
no curative treatment available [55] with 10 % of people
in the UK under 40 suffering from faecal and urinary
incontinence [56]. This figure increases to 24 % in people
over 40 years old [57, 58]. The most common cause of in-
continence in women is obstetric trauma that results in
injury to the anal sphincter muscles and loss of muscle
volume in old age [59]. New therapies are focusing on re-
generation of the smooth and skeletal muscles within the
sphincter to restore continence using tissue engineering
strategies [60]. One of the first in vivo studies targeting
faecal incontinence using biomaterials was published in
2013 by Kang et al. Myoblasts loaded onto PCL beads
were injected into a canine model of sphincter injury. Un-
fortunately, the study did not produce any evidence of
functional or histological improvement. However, the use
of myoblasts in combination with biomaterials is advanta-
geous, as myoblasts are particularly responsive to bioma-
terials. Their adhesion, differentiation and proliferation
can be affected by surface topography, microstructure and
mechanical properties [61, 62]. This effect could perhaps
be manipulated to achieve more cell proliferation or have
higher control of differentiation.
Shi et al. (2014) injected adipose-derived mesenchymal
stem cells (AdMSCs) attached to silk fibrin microspheres
into a model of urinary incontinence in rats. They found
that there was long-term improvement (12 weeks) in the
group administered cells attached to microspheres com-
pared to the controls, as well as an improvement in leak
pressure and decrease in lumen size [63]. These methods
could potentially be applied to a human sphincter defect,
specifically in the rhabdosphincter, which is thinner than
the external anal sphincter [64]. For larger muscles, a
porous scaffold may be more appropriate as they would
promote vascularisation of the tissue, which is vital in
regenerating healthy tissue.
Tracheal tissue engineering
There are many challenges in tracheal tissue engineering.
Clinically, tracheal stenosis, tracheomalacia, trauma due
to prolonged intubation and cancers can all result in irre-
versible damage to the trachea [65] with resection of the
trachea being the only treatment option available (up to
half in an adult and a third in children) [66]. Therefore,
there is a clear need for a suitable substitute of native tra-
cheal tissue. A successful tracheal replacement would have
to be biocompatible, have the rigidity to prevent collapse,
but allow the flexibility usually provided by the native tra-
chea. Once produced, the construct must also be able to
vascularise and regenerate ciliated epithelium to become
epithelialised [67]. Many different cell types, seeding tech-
niques and materials are studied for this approach.
The most common cell types investigated for tracheal
tissue engineering are chondrocytes and stem cells. The
native trachea consists of cartilage rings, hence, why chon-
drocytes are often used as they produce collagen and
aggrecan. Stem cells such as mesenchymal stem cells
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(MSCs), embryonic stem cells (ES) and induced pluripo-
tent stem cells (iPS) have the ability to differentiate into
many different cell lineages but, for this instance, are all
used for epithelial cell regeneration. The cells are cultured
with the scaffold to achieve re-epithelialisation similar to
the native trachea.
Decellularised scaffolds are often considered for tra-
cheal tissue engineering as they contain materials that
form the ECM such as collagen, fibrin and hyaluronic
acid [68], thus allowing cell adhesion, proliferation and
differentiation [69, 70]. However, natural materials lack
the mechanical integrity that synthetic materials provide
[9, 71]. Thus, there are numerous studies combining
natural materials, such as hydrogels with synthetic mate-
rials for tracheal tissue engineering to create a scaffold
with the benefits of both natural and synthetic materials.
Lin et al. (2011) combined PCL with a gelatin hydrogel
to produce a tracheal scaffold which in an in vivo model
showed suppression of the formation of scar tissue and
increased survival compared to the PCL scaffold alone
[72]. Growth factors can also be incorporated into
hydrogel materials to allow for their sustained release
over time within artificial trachea constructs. Tatekawa
et al. (2010) loaded gelatin hydrogels with bFGF. For this
purpose, bFGF could promote chondrogenesis and neovas-
cularisation. A PLGA and collagen mesh was implanted
around a defect in the tracheal rings of a rabbit; the scaffold
was reinforced with a biodegradable stent, and the bFGF-
loaded gelatin sheet was wrapped around the entire con-
struct. The results showed that including bFGF into the
scaffold resulted in improved cartilage regeneration within
the tracheal defect and re-epithelialisation was observed
after 6 months. It was reported that the construct had good
mechanical strength; this is likely due to the implanted
stent that would also prevent collapse [73]. Decellularised
tracheal scaffolds have been used to replace the trachea of
patients in various clinical trials [8]. A cadaver trachea is
decellularised using a harsh detergent-enzymatic treatment
that strips the extracellular matrix of any cells. The ECM
scaffold is then re-seeded in a bioreactor, often with the pa-
tient’s own cells [74]. This process allows for cells to effect-
ively attach and proliferate in a natural environment, and
such a transplant eliminates the need for immunosuppres-
sive therapy. Unfortunately, the decellularising procedure
can damage the ECM; residual cells may remain in the
scaffold, and the whole process requires a donor organ that
is not always available. These constructs can often collapse,
resulting in the need for recurrent implantation of stents
to keep the airway open. The insertion of stents has
been shown to lead to scarring and negatively affect re-
epithelisation [8]. Preventing the collapse of this hollow
organ has been at the forefront of research in the recent
years. Gonzalez-Molina et al. (2012) has shown that using
magnets to aid seeding of cells derived from connective
tissues results in a significantly higher cell attachment to
the scaffold compared to the use of established rotating/dy-
namic seeding methods [9, 75]. Park et al. (2015) designed
a poly(L-lactide-co-ε-caprolactone) (PLCL) and gelatin scaf-
fold that was rigid and flexible. The scaffold was seeded
with chondrocytes and functionalised with transforming
growth factor beta 1 (TGF-β1) growth factor to further
stimulate regeneration of the cartilage. The cellularised
scaffold was implanted, and in vivo studies showed that re-
generation of the cartilage similar to native cartilage had
been achieved and the organ did not collapse under com-
pression [76]. 3D printing has also been used to produce
scaffolds, Goldstein et al. (2015) printed polylactic acid
grafts into a collagen gel. Once seeded with chondrocytes
and implanted in vivo, the trachea became epithelialised
and a new cartilage was produced [77]. Engineering the tra-
chea has been successfully translated to the clinic [9]. Based
on the outcome of these early studies, ongoing research ad-
dresses the challenges that have been observed in order to
achieve an engineered construct with properties similar to
the native tissue (epithelialised surface, cartilage rings,
mechanical integrity to prevent collapse) [67].
Conclusions
Tissue engineering of hollow organ constructs is no lon-
ger in its infancy. Advancements in engineering allows for
a better understanding of the behaviour of biomaterials
and their fabrication in the context of hollow organ con-
struction. Biomaterials play an important role in under-
pinning many of the tissue engineering technologies being
developed for hollow organs. Selection of appropriate bio-
materials with suitable physicochemical properties is im-
perative to the success of hollow organ scaffold structures.
The fabrication processes available are continuing to
evolve to allow the shape, size, porosity, topography and
scalability of the scaffold to be controlled in order to meet
the tissue requirements [10]. Tissue engineering is a
widely studied field with many research groups moving on
from initial in vitro experiments to in vivo work, to further
understand the effect and impact of their respective ther-
apies in a more physiologically relevant environment, as
well as highlighting the advancements in current research.
With successes in recent clinical trials [7, 9], there is a
promise to effectively replace other hollow organs. Despite
this, there are still challenges that need to be addressed
for successful engineering of hollow organs. This will in-
clude achieving complete vascularisation of constructs to
ensure long-term survival in vivo. The success of engin-
eering hollow organs lies in effectively bringing material
engineering and biological principles together to address
unmet clinical needs. This interdisciplinary field is rapidly
developing and advancing, making for an exciting future
for tissue engineering and regenerative medicine.
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